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“Surgeons must be very careful 
When they take the knife 
Underneath their fine incisions 
Stirs the culprit –Life!” 
 
Emily Dickinson (1805-1886) 
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      Introduction 
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Carcinoma esophagus is the fifth most common malignancy world 
wide and occurs at a crude incidence rate of 5.5 per 100000 
population 1. It is unique among cancers of the gastrointestinal tract 
in that it traverses three anatomical compartments: the neck, thorax 
and the abdomen, and encompasses two different primary 
histologies: adenocarcinoma and squamous cell carcinoma. 
Natural history data and patterns of failure after specific treatment 
modalities provide an insight into the biologic tendencies of 
esophageal malignancy and suggest potential therapeutic avenues to 
explore.  
At presentation, the majority of patients have locally or regionally 
advanced or disseminated cancer, irrespective of histology 2. The 
lack of a serosal envelope and the rich submucosal lymphatic 
network of the esophagus provide a favorable milieu for extensive 
local infiltration by the tumor as well as lymph node involvement. 
Even if distant disease is not apparent clinically or radiologically at 
presentation, studies suggest that micrometastases are invariably 
present. This is borne out by the high incidence of distant sites as a 
significant and universally fatal component of failure 3. Bone marrow 
samples from ribs obtained during thoracotomy for esophagectomy 
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were shown to be positive for tumor cells by immunohistochemistry 
and polymerase chain reaction (PCR) studies in up to 90% of the 
patients sampled 4. The clinical significance of these findings is not 
known, but probably indicates the need to focus on systemic therapy 
in addition to loco regional treatment. 
Median survival after esophagectomy for patients with localized 
disease is 15 to 18 months with a 5-year overall survival rate ranging 
from 27 % to 30%. The patterns of failure are influenced by the site of 
the tumor and the histology. Loco regional recurrences predominate 
in tumors of the upper and middle third whereas distant failure is 
more common with adenocarcinomas arising in the lower esophagus 
3. 
The addition of chemotherapy, chemo radiotherapy or radiotherapy to 
surgery may alter patterns of failure but the reported results are not 
consistent. Incidence of distant metastases does not seem to be 
affected by any of these combinations, and thus improvement in 
survival rates will need a further stress on systemic modalities of 
therapy. 
We attempt to study the patterns of failure in patients who have been 
treated with different treatment modalities, and also to possibly 
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delineate the natural history of the malignancy by means of a 
retrospective analysis of the data on these patients. We hope that this 
study would lead to further research in decreasing the morbidity 
associated with treatment and contribute to a better understanding of 
the biology of carcinoma esophagus. 
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                                                        Objectives 
 12
1. To study the patterns of failure in patients of carcinoma 
esophagus treated with various modalities. 
2. To identify the treatment related morbidity and the means to 
reduce the same. 
3. To study the feasibility and validity of the sentinel node concept 
in carcinoma esophagus. 
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Methods 
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A total of 818 patients of carcinoma esophagus were seen in the 
outpatient department of our Institute during a ten year period from 
1995-2004. 
Of these 818 patients, only about 368 were considered suitable for 
some form of treatment after clinical assessment of the metastatic 
nature of the disease and performance status. 
A retrospective review of the records of all these patients was 
done. Data for 346 patients was available in full and was 
considered for analysis. 
Information regarding the demographic characteristics of the 
patient and the possible risk factors was collected. 
In addition, the clinical symptomatology, physical findings and 
imaging characteristics were also looked at. The extent of the 
tumor as determined by esophagoscopy and in most cases, CT 
scan of the chest and abdomen was also assessed. The general 
condition of the patients, pulmonary reserve as measured by a 
pulmonary function test and most importantly, the willingness of 
the patient to undergo major surgery or radiation therapy were the 
criteria used in selecting patients for a particular treatment 
modality. 
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The treatment modality chosen, the complications because of the 
treatment given and the response of the tumor to therapy was also 
documented. In patients who underwent surgery, the approach 
chosen, the extent of lymphadenectomy and the pathologic tumor 
and nodal status were recorded. 
The site of first failure and secondary treatment if given was also 
established. 
 
Sentinel node biopsy: 
The feasibility of a sentinel node biopsy was proposed to be 
prospectively examined in 6 patients of carcinoma esophagus. 
However, because of logistic reasons it could be done only in one 
patient. About 5 to 7 ml of patent blue dye was injected intra 
operatively, before mobilization of the esophagus was performed. 
As the diffusion of the dye would occur within two to three minutes, 
transmural injection of the dye into four quadrants at the level of 
the tumor was done.    
The node or nodes which were stained blue were dissected out 
and the appropriate level colour coded on a chart. These nodes 
were sent separately for histopathologic examination. The rest of 
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the surgery was completed as per the pre operative plan with the 
requisite lymph node dissection. The non-sentinel nodes which 
were found to be metastatic were marked on the same chart with a 
different colour.   
 
Statistical methods used:  
The data was analysed using the SPSS software. Frequency 
tables were generated by the software and used to convert the 
data into relevant clinical conclusions. Kaplan Meier curves were 
used to assess the expected survival of the different subsets 
within the cohort. The Cox regression test was used to determine 
statistically significant factors which affected survival. 
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Epidemiology and biologic factors 
Carcinoma of the esophagus is the sixth leading cause of death from 
cancer worldwide 5. According to the Madras metropolitan tumor 
registry (MMTR), it is the fourth most common cancer in males and 
sixth most common in females. The crude incidence rate is 5.5 per 
100000 men and 4.1 per 100000 women 1. More than 90% of 
esophageal cancers are either squamous cell carcinomas or 
adenocarcinomas. Malignancies arising in the upper or mid thoracic 
esophagus are usually squamous cell carcinomas, whereas 
adenocarcinomas arise more commonly in the distal esophagus 6. 
The lifetime risk of esophageal cancer is 0.8% for men and 0.3 % for 
women, and increases with age with a mean age at diagnosis of 67 
years 7. 
Once cancer develops it may spread rapidly: 14 to 21% of T1 lesions 
and 38 to 60% of T2 tumors are associated with lymph node 
involvement 8. At the time of diagnosis, about 50% of patients have 
either unresectable tumors or radiographically visible metastases. 
Although surgery is considered to be the mainstay of treatment of 
esophageal cancer, there are many factors which mitigate its 
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success. The esophagus lacks a serosa, and once the tumor 
penetrates the muscular layer, it can invade any of the surrounding 
structures. The submucosa is rich in lymphatics which spread 
longitudinally as well as laterally, and so submucosal spread of tumor 
especially proximally is common 9. The longitudinal network of 
lymphatics allows spread of the tumor to the neck, thorax and 
abdomen irrespective of the location of the tumor. Once a tumor has 
breached the muscular layer, the incidence of lymph node 
involvement exceeds 75% 9. Definitive therapy therefore should aim 
not only at loco regional control but also systemic control of disease. 
 
Natural history 
Carcinoma esophagus is often far advanced at the time of diagnosis 
and only a small number of patients are considered for curative 
therapy and possible long term survival. Resection rates vary from 19 
to 64% and 5 year survivals from 10 to 55% depending on the stage 
of the cancer. Surgical resection remains the backbone of therapy as 
it provides sustained palliation of dysphagia and the best chance for 
cure 10. Advances in surgical and anesthetic techniques have 
contributed to a significant decrease in the post operative mortality. 
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This has however not been converted into survival benefit as patients 
present with recurrent disease following apparently curative surgery. 
Hence attempts have been made to improve the survival by 
increasing the radicality of the lymphadenectomy or by combining 
surgery with other treatment modalities. An understanding of the 
sites, causes and timing of the recurrences will therefore point us in 
the right direction of attempting to improve the survival of these 
patients. 
Mariette et al detected loco regional recurrences in more than 50% of 
their patients who had undergone apparently curative 
esophagectomy within the first 3 years after surgery with an overall 5 
year survival rate of 41% 3. In their study distant failures were more 
common with malignancies of the lower third of the esophagus. 
Tumor depth appeared to be the only significant factor predictive of 
loco regional or distant failure. 
The frequency of distant failures has been shown in a few studies to 
be almost the same as that of loco regional failure (37% v/s 39%), 
with almost the same median time to failure (11 months v/s 13 
months). This suggests that micrometastases have already occurred 
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at the time of diagnosis and that these metastases grow more rapidly 
after the primary is resected 11.  
Some authors also believe that lymphatic and hematogenous 
metastases occur independent of each other, and this accounts for 
the distant failure in about 40% of patients who are lymph node 
negative 12. One prospective study demonstrated an incidence of 
88% micrometastases in the ribs and 15% in iliac bone marrow 
specimens of patients with localized carcinoma esophagus who 
underwent surgery 4. 
Hence there are two groups of patients who need to be identified: 
one, those patients with metastatic disease which is not picked up by 
the current modalities of investigation and two, those with 
micrometastases. The former group can be excluded from curative 
treatment options whereas the second group needs to be enrolled in 
trials of systemic therapy. 
 
Evolution of surgery for carcinoma esophagus 
With reduced perioperative morbidity and mortality, surgery remains 
an effective modality, either alone or in combination with other 
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approaches, in providing local tumor control with durable relief of 
dysphagia, and the potential for a prolonged disease free survival. 
Selection of the optimal approach depends on the tumor location, 
histology, extent of local resection and lymphadenectomy, 
anastomotic site, performance status and most importantly the 
surgeon’s experience. No prospective trial has shown a survival 
advantage to any one approach 13. 
Transhiatal esophagectomy (THE) entails mobilization and 
resection of the intra thoracic esophagus and limited nodal dissection 
through an abdominal and neck incision, without a thoracotomy. This 
procedure requires less operating time than the trans thoracic 
approach and avoids the complications of a thoracotomy. As initially 
described by Denk 14 and re introduced by Orringer and Sloan 15, this 
approach does not afford direct visualization of middle or proximal 
third tumors thus limiting the ability to perform a complete intra 
thoracic lymphadenectomy and increasing the potential for injury to 
the intra thoracic structures. Reported survival rates range from 22% 
to 27%. 
Transthoracic esophagectomy (TTE) involves resection of the 
esophagus and associated lymphatic tissue and is performed through 
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a thoracotomy and laparotomy incision. Upper and mid thoracic 
lesions are approached through a right thoracotomy whereas lower 
esophageal cancers can be approached through the left side. Initially 
described by Lewis 16 in 1946, this technique offers excellent 
exposure and theoretically allows for a more definitive oncologic 
procedure. The three incision approach of McKeown 17 with a cervical 
incision, right thoracotomy and laparotomy combines the advantages 
of a cervical anastomosis with the exposure of an Ivor- Lewis 
procedure. The most common post operative complications include 
respiratory compromise (atelectasis, pneumonia and empyema); 
anastomotic leak with mediastinitis and wound infections 18. 
En bloc esophagectomy was initially proposed by Logan in 1963 
and modified by Skinner in 1969 19. It entails en bloc resection of the 
thoracic esophagus with the azygous vein, thoracic duct, mediastinal 
pleura and pericardium through a thoracotomy. Local recurrence 
rates are less than 10% and when compared to limited resections, en 
bloc esophagectomy has provided improved survival 20.      
Two large reviews comparing transhiatal (THE) and transthoracic 
esophagectomy (TTE) have been published. Both reviews found a 
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significantly higher operative mortality among patients resected by 
TTE (9.5% v/s 6.3%). A higher anastomotic leak rate was reported for 
THE; however, when a leak occurred in a patient who had undergone 
trans thoracic esophagectomy, the mortality was much higher 
because of the associated mediastinitis. Recurrent laryngeal nerve 
palsy was found to be higher with the transthoracic approach. Cancer 
related survival appeared to be the same with both approaches 21, 22 
A standard lymphadenectomy involves the removal of the 
periesophageal and perigastric nodes. In addition to a thorough 
mediastinal dissection extending from the carina to the hiatus, an 
upper abdominal dissection along the hepatoduodenal ligament, 
celiac axis, left gastric and splenic arteries is accomplished in a two-
field lymph node dissection 23. A three-field lymphadenectomy 
extends the dissection to the superior mediastinum including nodes 
along the right and left recurrent laryngeal nerves and through a 
separate collar incision in the neck, completes the dissection with 
removal of the lower cervical nodes 24. Altorki et al reviewed a series 
of patients who underwent three field dissection, with a post operative 
mortality of 5.1% and a respiratory complication rate of 24%. The 4 
year survival was 41.5% which was significantly better than the 
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standard resection group 25. A group at Cornell University examined 
80 patients who underwent three field lymphadenectomy. Over all 30 
day mortality was 5% with a respiratory complication rate of 16%, 
anastomotic leak rate of 11% and a 9% incidence of recurrent 
laryngeal nerve palsy. Over all 5 year survival was 51%. The 
incidence of cervical nodal metastases was about 36% and the 
survival in this sub group was only 25% 26. 
Radiation therapy (RT) and ChemoRT in the treatment of 
carcinoma esophagus 
Several large randomized trials have been conducted to explore 
issues relating to the multi modality treatment of esophageal cancer. 
Unfortunately, however, the standard of care remains controversial. 
Kelsen et al reported the results of an Intergroup trial for 440 patients 
with potentially resectable carcinoma of the esophagus. Patients 
were randomized to surgery alone or preoperative chemotherapy 
followed by surgery. Those patients whose disease was responsive 
or stable received post operative chemotherapy. Only about 52% of 
the patients eligible to receive post operative chemotherapy actually 
did so. The median survival of patients treated with preoperative 
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chemotherapy was 14.9 months and for those treated with surgery 
was 16.1 months 27. 
Clark et al demonstrated a survival of16.8 months for patients who 
received pre operative chemotherapy when compared to 13.3 months 
for patients who did not 28. 
There have been numerous trials of chemoradiation versus surgery. 
Walsh et al reported the results of an Irish trial in which patients were 
treated with surgery or preoperative chemoradiation. Median survival 
was 16 versus 11 months in favor of the chemoradiation arm 29. 
The EORTC (European Organisation for Research and Treatment of 
Cancer) conducted a multi center trial comparing preoperative 
chemoradiation to surgery alone in patients with Stage I and II 
squamous cell carcinoma. There was no survival difference between 
the two arms with a median survival of 18.6 months and a 3 year 
survival of 36% 30. 
Urba et al were also unable to demonstrate any significant survival 
advantage for chemoradiation 31. 
A multi institutional trial headed by RTOG (Radiation Therapy 
Oncology Group) was reported in 1992 comparing patients who were 
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randomized to receive treatment with radiation alone versus those 
who received radiation with two courses of concurrent chemotherapy 
followed by two more courses of chemotherapy. The median survival 
was 14.1 months and 5 year survival was 27% in the chemoradiation 
arm; median survival was 9.3 months with no patients alive at 5 years 
in the radiation alone arm 32. 
Hence, surgery remains the standard of care for patients with 
resectable disease. Definitive chemoradiation is the treatment of 
choice for patients considered unfit for surgery. There is no definitive 
evidence that chemoradiation plus surgery is superior to surgery 
alone. 
Role of sentinel node biopsy in carcinoma esophagus 
In the surgical management of carcinoma esophagus, radical lymph 
node dissection has played a significant role in the twentieth century. 
Survival benefit of three field lymphadenectomy for esophageal 
cancer has been shown by Japanese researchers 24. The feasibility 
of radical lymphadenectomy and the demonstration of a convincing 
survival benefit in the face of the considerable morbidity is still an 
issue in the Western world. Secondly, completion of radical 
lymphadenectomy in minimally invasive procedures is still difficult. 
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Therefore, determination of optimal extent of lymph node dissection 
based on actual node status is required. A sentinel node sampling is 
a step in this direction. 
A sentinel node is defined as the first draining node from the primary 
lesion and the first possible site of metastasis 33. Orderly progression 
of lymph node metastases has been well documented in breast 
cancer and melanoma. The validity of the sentinel node concept for 
gastro intestinal cancers has not however been verified. 
Kitagawa et al described their technique of detection of sentinel 
nodes in carcinoma esophagus using radioactive technetium 99m- tin 
colloid. The tracer was injected sub mucosally through an endoscope 
at the site of the tumor about seven hours prior to surgery, and a 
hand held gamma probe was used intra operatively to localize the 
sentinel node. Sentinel nodes were located in the first nodal basin 
based on anatomic classification only in 15% of the patients. The 
detection rate was 91% with a sensitivity of 86% 34. 
Burian et al reported an 85% detection of sentinel lymph nodes in 
adenocarcinomas of the lower esophagus with a specificity of 75%. 
They used a combination of blue dye and radio tracer 35. 
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In a study by Kato et al, the sensitivity of the sentinel node procedure 
was 86.7% and the false negative rate was 8.7%. Occult metastasis 
was detected by cytokeratin staining in 1.7% of the lymph nodes 36. 
These studies show that the sentinel node concept is valid even for 
upper gastro intestinal cancers with multi directional and complicated 
lymphatic flow. The relatively high incidence of anatomic skip 
metastases can be attributed to the aberrant distribution of the 
sentinel lymph nodes. An individualized and minimally invasive 
surgical approach can be applied to the management of esophageal 
carcinoma based on the sentinel node status. 
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Table 1: Demographic profile: Age wise distribution (N=346) 
 
Age group Number Percentage 
<30 years 14 4.0 
31-39 years 59 17.0 
40-49 years 88 25.4 
50-59 years 109 31.5 
60-69 years 64 18.5 
>70 years 12 3.5 
Total 346 100 
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Figure 1: Gender wise distribution 
 
65%
35%
Male Female
 
As the above data shows, about 65% of the patients were male and 
about one third belonged to the sixth decade.  
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Table 2: Clinical features – symptomatology 
(N=346) 
 
SYMPTOM NUMBER PERCENTAGE 
Dysphagia 335 96.8 
Chest pain 10 2.9 
Hoarseness 1 0.3 
Total 346 100 
 
 
 
Table 3: Risk factor- smoking 
(N=346) 
 
SMOKING NUMBER PERCENTAGE 
Yes 189 54.6 
No 157 45.4 
Total 346 100 
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Table 4: Risk factor- alcohol intake 
(N=346) 
 
ALCOHOL NUMBER PERCENTAGE 
Yes 79 22.8 
No 267 77.2 
Total 346 100 
 
 
Table 5: Risk factor- family history 
(N=346) 
 
FAMILY HISTORY NUMBER PERCENTAGE 
Present 37 10.7 
Absent 309 89.3 
Total 346 100 
 
Dysphagia was the most common presenting symptom and about 
55% were long term smokers. Alcoholism and family history were 
present only in a few of the patients 
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Table 6: Tumor profile according to histology and site 
 
1 Gastrointestinal stromal tumor 
 
Squamous cell carcinoma was the most common histology 
constituting 92.7% of all the tumors. The mid thoracic esophagus was 
the commonest site (58.6%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SQUAMOUS 
CELL  
CARCINOMA 
ADENO 
CARCINOMA
BARRETT’S GIST1 TOTAL 
Cervical 
esophagus 
16 0 0 0 16 
Upper third 41 0 0 0 41 
Middle third 199 4 0 0 203 
Lower third 66 18 1 1 86 
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Table 7: Primary treatment offered 
(N=346) 
 
MODALITY NUMBER  PERCENTAGE 
RT1 183 52.9 
Chemo RT2 44 12.7 
Surgery 108 31.2 
Supportive care 11 3.2 
Total 346 100 
 
1 External beam radiation therapy 6500 cGy 
2 Concurrent chemoradiation with cisplatin and 5 FU 
 
 
31% were considered suitable for surgery on the basis of their 
performance status, staging investigations and pulmonary reserve. 
75.6% of patients were treated either with radiotherapy alone or with 
concurrent chemo radiotherapy depending on their performance 
status and intent of treatment. 11 patients were initially considered 
suitable for treatment but on re evaluation were either found to have 
metastatic disease or poor general condition unsuitable for any form 
of therapy. 
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Table 8: Response to RT 
(n=183) 
 
RESPONSE NUMBER PERCENTAGE 
No response 10 5.4 
Partial response 50 27.3 
Complete response 123 67.2 
Total 183 100 
 
 
Nearly 70% of the patients who were treated with radiotherapy or 
chemo radiotherapy achieved a complete response of the primary 
tumor as assessed by endoscopy and symptomatic relief. 
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Table 9: Type of surgery performed 
(n=108) 
 
SURGERY NUMBER PERCENTAGE 
Trans hiatal 54 50 
Two field 11 10.1 
Trans thoracic 24 22.2 
Inoperable 19 17.6 
Total 108 100 
 
 
As mentioned earlier, about 108 patients were taken up for surgery. 
19 of these patients were found to be inoperable either due to peri 
esophageal extension of the tumor infiltrating the lefty main bronchus 
or aorta or due to dissemination in the form of liver metastases or 
peritoneal deposits. The site of the lesion and the performance status 
were used to decide the surgical approach. 
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Table 10: Major complications of surgery 
(n=89) 
 
SURGERY (N) ANASTOMOTIC 
LEAK (%) 
RIGHT 
RLN1 PALSY 
(%) 
LEFT RLN 
PALSY (%) 
Trans hiatal (54) 15(27.7%) 1(1.8%) 8(14.8%) 
Two field (11) 1(9.1%) 0 0 
Trans thoracic (24) 10(41.6%) 2(8.3%) 10(40.1%) 
 
1 Recurrent laryngeal nerve 
 
 
Anastomotic leak and recurrent laryngeal nerve palsy were the two 
most common complications of surgery which led to increased 
morbidity. About 41% of patients who underwent trans thoracic 
esophagectomy had a leak and almost half (48.4%) of them had 
recurrent laryngeal nerve palsy. 
 
 
 
 
 
 
 
 
 
 40
 
 
Table 11: Status of the cohort as of June 2006 (N=346) 
 
STATUS NUMBER PERCENTAGE 
Alive; NED1 76 22.0 
Alive with disease 1 0.3 
Dead of disease 191 55.2 
Dead unknown cause 65 18.8 
Dead of treatment complications 5 1.4 
Lost to follow up 8 2.3 
Total 346 100 
 
1 No evident disease 
 
 
 The follow up of these patients ranged from 5 months to 134 months 
with a median of 66 months. 8 patients (2.3%) were lost to follow up. 
Out of the 346 patients on whom data is available, 76 (22%) are alive 
with no evidence of disease. 1 patient has been detected to have 
mediastinal recurrence and is alive. 
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Table 12: Sites of failure in the cohort 
(n=338) 
 
FAILURE SITE NUMBER PERCENTAGE 
NED1 76 22.5 
Esophagus 148 43.7 
Mediastinum 8 2.3 
Neck nodes 15 4.4 
Liver 9 2.6 
Peritoneal deposits 6 1.7 
Skeletal metastases 5 1.4 
Brain metastases 1 0.3 
Pulmonary metastases 2 0.6 
Skin nodules 1 0.3 
Second primary 3 0.9 
Unknown 64 18.9 
Total 338 100 
 
1No evident disease 
 
Irrespective of the histology and treatment modality chosen, the 
esophagus remained the most common site of failure followed by a 
percentage of patients in whom the failure site could not be 
documented. The supraclavicular nodes were the next common site 
of failure. 
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Table 13: Correlation between histology and site of failure 
 (n=198)
FAILURE SITE SQUAMOUS CELL  
CARCINOMA (%) 
ADENO 
CARCINOMA(%) 
TOTAL 
Esophagus 145 (73.2) 3 (1.5) 148 
Mediastinum 6 (3.0) 2 (1.0) 8 
Neck nodes 11 (5.5) 4 (2.0) 15 
Liver 8 (4.0) 1 (0.5) 9 
Peritoneal deposits 3 (1.5) 3 (1.5) 6 
Skeletal metastases 5 (2.5) 0 5 
Brain metastases 1 (0.5) 0 1 
Pulmonary metastases 2 (1.0) 0 2 
Skin nodules 1 (0.5) 0 1 
Second primary 3 (1.5) 0 3 
Total 185 13 198 
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Table 14: Correlation between primary treatment and site of 
failure (n=271) 
 
 
FAILURE SITE RT1  CHEMO 
RT2 
SURGERY TOTAL 
(N) 
NED3 19 11 46 76 
Esophagus 115 16 17 148 
Mediastinum 1 1 6 8 
Neck nodes 6 3 6 15 
Liver 2 3 4 9 
Peritoneal 
deposits 
0 0 6 6 
Skeletal 
metastases 
5 0 0 5 
Brain 
metastases 
1 0 0 1 
Pulmonary 
metastases 
1 0 1 2 
Skin nodules 1 0 0 1 
 
1 External beam radiotherapy 
2 Concurrent chemo radiotherapy 
3 No evident disease 
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Table 15: Correlation between primary treatment and present 
status (N=346) 
 
 
PRESENT 
STATUS 
RT1 
(%) 
CHEMO 
RT2 (%) 
SURGERY 
(%) 
SUPPORTIVE 
CARE (%) 
Alive; NED 19 
(10.4) 
11 (25) 46 (42.6) 0 
Alive with 
disease 
0 0 1 (0.9) 0 
Dead of disease 121 
(66.1)   
21 (47.7) 42 (38.8) 7 (63.6) 
Dead unknown 
cause 
41 
(22.4) 
10 (22.7) 14 (12.9) 0 
Dead of 
treatment 
complications 
2 (1.1) 2 (4.5) 1 (0.9) 0 
Total 183 44 108 11a 
 
a Data unavailable for 4 patients in this group 
1 External beam radiation therapy 
2 Concurrent chemo radiotherapy 
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Table 16: Correlation between pathologic tumor stage and 
present status (n=94) 
 
 
STATUS T1 (%) T2 (%) T3 (%) T4 (%) 
Alive; NED 1(100) 14(77.7) 28(46.6) 2(13.3) 
Alive with disease 0 0 1 (1.6) 0 
Dead of disease 0 2 (11.1) 20(33.4) 12 (80) 
Dead unknown cause 0 2 (11.1) 10(16.7) 1(6.7) 
Dead of treatment  
Complications 
0 0 1 (1.6) 0 
Total 1 18 60 15 
 
 
A greater percentage of patients with pT2 tumors (78%) were alive 
when compared to pT3 (48%) and pT4 (13%) tumors. 
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Table 17: Correlation between pathologic nodal status and 
present status (n=91) 
 
 
STATUS N01 
(%) 
RLN2
(%) 
PERI 
ESOPHAGEAL 
(%) 
PERI 
GASTRIC 
(%) 
Alive; NED 
 
 
26 
(59.1) 
5 
(41.7) 
13 (43.3) 2 (40) 
Alive with  
Disease 
 
1 (2.2) 0 0 0 
Dead of disease 
 
9 
(19.8) 
5 
(41.7) 
12 (40) 3 (60) 
Dead unknown 
cause 
7 
(15.4) 
2 
(16.6) 
5 (16.6) 0 
Dead of 
treatment 
complications 
1 (2.2) 0 0 0 
 
Total 
 
44 
 
12 
 
30 
 
5 
1 Node negative  
2 Nodes along the recurrent laryngeal nerves and  
  paratracheal nodes 
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Table 18: Correlation between perinodal spread of tumor and 
present status (n=88) 
 
STATUS ABSENT (%) PRESENT (%) 
Alive; NED 39 (57.3) 6 (35) 
Alive with disease 1 (1.4) 0 
Dead of disease 16 (23.5) 11(55) 
Dead unknown cause 11 (16.1) 2 (10) 
Dead of treatment complications 1 (1.4) 0 
Total 68 20 
 
 
Most patients with metastatic nodes were dead with no significant 
difference found between positivity of recurrent laryngeal and peri 
esophageal nodes (58.3% v/s 56.6%). However 65% of patients with 
perinodal spread were dead when compared to 39.6% of patients 
who did not have perinodal extension. 
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Figure 2: Factors influencing survival – pathologic tumor status 
(univariate analysis) 
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The median survival for patients with pT2 tumors was found to be 48 
months, whereas that for pT3 was about 18 months to yield a p value 
of 0.05 on univariate analysis. 
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Figure 3: Factors influencing survival – histology (univariate 
analysis) 
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DFS – disease free survival in months. 
 
There was no significant survival difference between the histologic 
variants of the esophageal tumor. 
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Figure 4: Factors influencing survival – Nodal status (univariate 
analysis) 
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DFS – disease free survival in months 
 
 
The median survival of node negative patients was 50 months 
whereas that for node positive patients was 31 months only (p<0.05). 
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Figure 5: Factors influencing survival – perinodal spread 
(univariate analysis) 
 
Survival Function
STATUS1 = dead
DFS1
140120100806040200-20
C
um
 S
ur
vi
va
l
1.2
1.0
.8
.6
.4
.2
0.0
-.2
Perinodal spread
present
absent
 
 DFS – disease free survival in months 
 
 
In patients with nodal positivity, those with perinodal spread had a 
median survival of only about 24 months, whereas those without 
perinodal spread had a median survival of 32 months (p=0.05). 
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a  Data available for 346 patients.
Total number of patients  
seen in the OP N=818 
Number of patients 
treated N = 368a 
RT 
n= 183 
Surgery 
n= 108 
Supportive 
care n=11 
Complete 
response 
n=123 
Partial 
response 
n=50
No 
response 
n=10
Alive 
n=20 
Dead 
n=103 
Alive 
n=2 
Dead 
n=48 
Dead 
n=10 
Dead 
n=61 
Alive 
n=46 
Figure 6: Summary of the study 
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          Discussion 
 54
Esophageal cancer is a malignancy where refinements of surgical 
technique and the evolution of more radical procedures have not 
resulted in a proportionate increase in survival. As surgeons become 
more radical in their approach, the morbidity of the procedures 
increases and the quality of life of the patients decreases. Hence the 
thrust of future research will be on minimally invasive surgery, 
tailoring the nodal dissection according to the nodal status and newer 
adjuvant and neo adjuvant therapies. 
The age and gender distribution of our cohort roughly parallels that of 
other studies and the report of the IARC (International Association for 
Research against Cancer)1, 2. Most patients are male and the single 
largest group belonged to the sixth decade. Also these males who 
developed esophageal cancer were long term smokers (55%), but the 
consumption of alcohol (22%) was surprisingly low in contrast to 
other reports on the etiology of esophageal malignancy 7. 
Most patients who presented to the out patient department of our 
Institute were found to have metastatic disease at presentation or 
were found to have too poor a performance status to be considered 
for any kind of therapy. Consequently, of the 818 patients of 
esophageal cancer seen during the period of study, only about 368 
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(45%) patients were accepted for treatment. Studies by Pisani et al 
and data from the National Cancer Institute reflect the same trend 
wherein about 50% of newly diagnosed patients of esophageal 
cancer are found to be unsuitable for definitive treatment either due to 
metastatic disease or due to loco regionally advanced tumors 5, 7.    
Patients were considered good candidates for surgery on the basis of 
their performance status (0 or 1) and an objective assessment of their 
pulmonary function. Those patients who were not willing to undergo 
surgery were offered radiation therapy or concurrent chemo 
radiotherapy. As the data covers the period between 1995 and 2004, 
and the benefit of concurrent chemo radiotherapy had not yet been 
convincingly demonstrated in the earlier half of the study period, there 
is a relatively smaller number of patients (12.7%) in the concurrent 
chemo radiotherapy group. 
Primary therapy for esophageal cancer is either surgical or non 
surgical. For several reasons this results in a selection bias against 
non surgical therapy. First, patients with unfavorable prognostic 
features are selected for treatment with non surgical methods. 
Second, surgical series report results based on pathologic staging 
whereas non surgical series rely on clinical and radiologic staging. 
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Third, because some patients treated without surgery are approached 
with a palliative intent, sub optimal doses of radiation or 
chemotherapy may have been used. 
Many studies have reported results using external beam radiation 
therapy alone. Most include patients with unfavorable features like T4 
disease and multiple positive nodes. The use of radiation as a 
potentially curative modality requires doses of at least 5000 c GY at 
180 to 200 c GY per fraction. Shi and colleagues reported a 33% 5 
year survival rate with the use of accelerated fractionation to a total 
dose of 68.4 Gy 37. However, in the radiation therapy alone arm of 
the RTOG 85-01 trial (Radiation Therapy Oncology Group), all 
patients were dead of disease by three years 32.  
Our data has a higher percentage of patients with complete response 
to RT (70%), but the 5 year survival is a dismal 13%. This can be 
explained by the fact that the response to treatment was assessed by 
endoscopy alone and hence there may not have been pathologic 
complete response in the majority of these patients. None of the 
patients received radiation therapy or concurrent chemo radiotherapy 
as  neoadjuvant therapy and none of the patients who had a residue 
after therapy were considered for surgery. 
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Though only a small number of patients were treated with concurrent 
chemo radiation therapy (44), the 5 year survival of this group (25%) 
correlates well with the results of Herskovic et al(5 year survival of 
27%) 32 .  
The nature of surgery offered was decided by the site of the tumor, 
loco regional extent, the performance status and the pulmonary 
function. More than 50% of the patients underwent a trans hiatal 
esophagectomy, with trans thoracic esophagectomy being performed 
in 22%.  
Hulscher et al randomized patients into two surgical arms: trans hiatal 
versus trans thoracic. They found that the ICU stay and the hospital 
stay in the post operative period was significantly more in the trans 
thoracic group. However, the 5 year overall survival between the two 
arms was not significantly different (29% versus 39%) 38. 
The two most common complications in our study which led to 
increased hospital stay were anastomotic leak and recurrent 
laryngeal nerve palsy. Our documented leak rate was 28% in the 
trans hiatal group and about 41% in the trans thoracic group. 
Recurrent laryngeal nerve palsy was found in 14% of patients who 
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underwent a trans hiatal esophagectomy and in 40% of patients who 
underwent a trans thoracic esophagectomy. 
These percentages are much higher than the published rates of 10-
15% of anastomotic leak and about 12-14% recurrent nerve injury in 
various studies, and can only be attributed to the surgeons’ learning 
curve. 
In spite of the higher incidence of post operative morbidity compared 
to other published studies, the 5 year overall survival of the surgical 
arm of the study population is about 42%, which compares well with 
the best of studies. 
A study published by the MD Anderson Cancer Center attempted to 
determine the difference in natural history and prognosis between 
squamous cell carcinoma and adenocarcinoma of the esophagus. 
They found that the incidence of nodal spread and distant metastases 
was slightly higher in patients with adenocarcinoma. However, the 
disease free survival and the overall survival was the same in both 
groups 39 . 
This is reflected in our data which show no significant survival 
difference between the two major histologic variants. 
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Mariette et al pointed out that in their study the only factor which 
predicted disease recurrence and survival was the pathologic tumor 
status. However they were unable to demonstrate the effect of nodal 
positivity on survival 3. Tabira et al in their study of patients who 
underwent trans thoracic esophagectomy determined age, T4 tumors 
and number of metastatic nodes as the factors which influenced 
survival 40. 
In our study, pathologic tumor status, nodal positivity and peri nodal 
spread were the factors which affected survival on univariate 
analysis. However, on multivariate analysis, only peri nodal status 
seemed to be statistically significant. 
The esophagus, mediastinum and the supra clavicular nodes were 
the most common sites of failure irrespective of the histology and the 
treatment modality. 
Dresner et al reported a 21% local recurrence rate following a radical 
esophagectomy, which is much lower than that reported in series 
where no formal lymphadenectomy has been done. However, some 
node positive patients had a 5 year survival of 39%, which confounds 
the influence of nodal dissection on survival. This probably can be 
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explained by the absence of peri nodal spread conferring a relative 
survival advantage in this subset of patients 41.  
The demonstration of an improvement in survival of patients who 
underwent three field lymphadenectomy by Japanese surgeons 
needs to be carefully balanced by the additional morbidity of 
increased vocal cord paralysis. 
A via media between the radicality of a three field lymphadenectomy 
and the inadequate lymph node dissection of trans hiatal 
esophagectomy is the sentinel node biopsy procedure. Further 
oncologic research needs to focus on this aspect along with newer 
modalities of adjuvant/ neo adjuvant therapy in the attempt to improve 
survival in esophageal cancer.   
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Summary and 
conclusions 
 
 
 
 
 62
A total of 818 patients of carcinoma esophagus were seen in the out 
patient department of our Institute in the period 1995-2004. 
Of these, about 368 patients (44.9%) were offered treatment of some 
kind. 
65% of these patients were male and about 31.5% belonged to the 
sixth decade. 
About 97% of the cohort presented with dysphagia. 
55% of the patients were smokers whereas only about 23% gave 
history of long term alcohol intake. 
52.6% of all tumors were located in the mid thoracic esophagus and 
92.7% of all tumors were squamous cell carcinomas. 
31.2% of the cohort were considered suitable for surgery.  
Of the 227 patients who were offered radiotherapy or chemo 
radiotherapy, 157 (69.1%) had a complete response. 
Only 13.2% of the patients treated with radiation therapy were alive at 
5 years. 
129 patients (82.1%) of those who had a complete response were 
dead at 5 years. 
108 patients underwent surgery, of which 54 (50%) were trans hiatal 
esophagectomies. 
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28% of the patients who underwent trans hiatal esophagectomy and 
41% of the patients in the trans thoracic esophagectomy group 
developed an anastomotic leak. 
14% of the patients in the trans hiatal group and 41% of the trans 
thoracic group had vocal cord palsy.  
 26.7% of the patients in the surgery arm developed loco regional 
recurrences. Most of these recurrences were in the first three years 
after the surgery. 
About 42.6% of the surgery arm as a whole was alive at 5 years. 
78% of patients with pT2 tumors were alive at 5 years when 
compared to 48% of patients with pT3 tumors and 13% of pT4 
tumors. 
The median survival of patients with node negative disease was 50 
months whereas that of node positive patients was 31 months. 
65% of patients with perinodal spread of tumor were dead at 5 years. 
 
This retrospective study of 346 patients of esophageal cancer 
demonstrates the dismal survival rates achieved with radiation 
therapy alone, which seem to be improved dramatically with the 
addition of concurrent chemotherapy. No definitive claims can be 
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made on this front however, in view of the small number of patients 
administered chemoradiation therapy. There was a high rate of 
complications with the surgical arm, though the 5 year survival 
achieved approximated the best in available literature. Pathologic 
tumor stage, nodal positivity and peri nodal spread were found to be 
prognostic on univariate analysis, however only peri nodal extension 
of tumor was the only factor found to be statistically significant on 
multivariate analysis. Hence a balance needs to be struck between 
the survival benefit of extended lymph node dissections and the 
consequent complications. Sentinel node biopsy offers a simple and 
efficient means of achieving this and further research should be in 
this direction.   
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